|
Animalcare Group PLC - York, England-based veterinary services and pharmaceuticals firm - Enters into agreement with 272Bio Ltd to develop and commercialise a novel biological treatment for sweet itch in equines, a group of mammals that includes horses, donkeys and zebras. Sweet itch, which is a common condition among equines, affects around 8% of horses globally. Animalcare adds that the annual addressable market is estimated to be worth between €150 million and €200 million globally. ‘The programme is at an early stage and will initially focus on preclinical research with the aim of achieving proof of concept over the next 18-24 months,’ it says. The firm adds: ‘This licence agreement and research collaboration is another exciting step forward in the development of its equine franchise, which was enhanced in Q1 2025 with the acquisition of Randlab, an exclusively equine focussed business based in Australia.’ Animalcare Chief Executive Officer Jenny Winter says: ‘This is an exciting step forward in our long-term strategy, building our equine franchise and establishing a pipeline of innovative products that bring benefits to horses in large and growing segments of the market. This collaboration also strengthens our partnership with 272Bio, who are specialists in the antibody field, and we look forward to working closely with them on this development.’ Current stock price: 248.80 pence each, closed 0.5% lower on Wednesday in London 12-month change: up 2.0% Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
